Biomarkers are now an integral part of the drug discovery and development process, acting as indicators of drug mechanism of action, efficacy, safety and disease progression, as well as assisting in disease diagnosis, patient selection and clinical trial design. Biomarkers also offer the potential to inform treatment decisions and bring personalized medicine into clinical practice.
Latest advances in clinical and translational biomarkers will be covered, including patient selection and predicting response to therapy, liquid biopsy and cell free DNA, companion diagnostics and personalized medicine, biomarker assay development and validation, and biomarker-based clinical trials. The new frontier of digital health and its impact on drug and diagnostic development will be explored, covering emerging digital biomarkers and their utility in clinical trials, advances in biosensors and wearables as clinical endpoints, integration of mobile health into drug development, and the latest applications in point-of-care testing and remote patient monitoring.
The training program is aimed at PhD students, but welcomes the participation of external academic and scientific community members